Biogen (BIIB) Misses Q4 EPS by 19c, Revenue Beats; Offers Outlook

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. ANET
7. SWKS
8. XYZ
9. CVS
10. SPY

Go back to Biogen (BIIB) Misses Q4 EPS by 19c, Revenue Beats; Offers Outlook

Biogen Reports Record Revenues for Both the Full Year and Fourth Quarter of 2017, $12.3 Billion and $3.3 Billion, Respectively

January 25, 2018 6:29 AM EST

2017 total revenues grew 7% or 15% excluding hemophilia revenues*

2017 GAAP EPS decreased 30%, including a $1.2 billion charge due to U.S. tax reform

2017 non-GAAP EPS grew 8%

Company added seven clinical programs to neuroscience pipeline in 2017

Company provides 2018 full year revenue guidance of $12.7 to $13.0 billion

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Biogen Inc. (Nasdaq: BIIB) today reported full year and fourth quarter 2017 financial results, including:

Full year total revenues of $12.3 billion, a 7% increase versus the prior year or a 15% increase... More